There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ginkgo Bioworks Holdings (DNA – Research Report) and Sagimet Biosciences, Inc. Class A (SGMT – Research Report) with bullish sentiments.
Ginkgo Bioworks Holdings (DNA)
In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on Ginkgo Bioworks Holdings, with a price target of $3.00. The company’s shares closed last Monday at $1.66.
According to TipRanks.com, Goparaju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Ginkgo Bioworks Holdings has an analyst consensus of Hold, with a price target consensus of $2.69.
See the top stocks recommended by analysts >>
Sagimet Biosciences, Inc. Class A (SGMT)
In a report released yesterday, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, with a price target of $30.00. The company’s shares closed last Monday at $12.31.
According to TipRanks.com, Wolleben is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sagimet Biosciences, Inc. Class A with a $43.33 average price target, implying a 250.9% upside from current levels. In a report issued on August 8, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $33.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DNA:
- Cathie Wood’s ARK Investment bought 297.5K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 850K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 6.43M shares of Ginkgo Bioworks today
- Ginkgo Bioworks sees FY23 revenue $245M-$260M, consensus $292.83M
- Ginkgo Bioworks reports Q2 EPS (9c), consensus (8c)
